ImmunityBio, Inc. (NASDAQ: IBRX) announced that its innovative therapy Anktiva® (nogapendekin alfa inbakicept) in combination with BCG has been approved by the European Commission for the treatment of patients with carcinoma in situ (CIS) of non-muscle invasive bladder cancer (NMIBC).

ImmunityBio, Inc. (NASDAQ: IBRX) announced that its innovative therapy Anktiva® (nogapendekin alfa inbakicept) in combination with BCG has been approved by the European Commission for the treatment of patients with carcinoma in situ (CIS) of non-muscle invasive bladder cancer (NMIBC).

老虎证券2026/02/18 14:15

Show original

This authorization marks that the therapy has obtained marketing approval in 33 countries, including the 30 member states of the European Economic Area (EEA) as well as Iceland, Liechtenstein, and Norway, which will significantly enhance global patients' access to this cutting-edge treatment option.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

ImmunityBio, Inc. (NASDAQ: IBRX) announced that its innovative therapy Anktiva® (nogapendekin alfa inbakicept) in combination with BCG has been approved by the European Commission for the treatment of patients with carcinoma in situ (CIS) of non-muscle invasive bladder cancer (NMIBC).

You may also like

Trending news

Crypto prices